Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2016

View Archived Issues

Valneva develops Zika virus vaccine

Phase III S-TRAC study of sunitinib meets primary endpoint

Design of a novel dimeric compound that targets the pathogenic RNA in spinocerebellar ataxia 10

Results from phase III LUNAR study of LBN 0.024% in open-angle glaucoma or ocular hypertension

Anti-tau antibody enters phase I trials, AC Immune eligible to receive milestone payment

Proteostasis Therapeutics patents CFTR channel correctors

Gilead Sciences obtains European marketing authorization for Epclusa

Evotec collaborates with Antibiotic Research UK to tackle antibiotic resistance

Ligand Pharmaceuticals and Gilead Sciences enter OmniAb agreement

FDA approves use of SurePath Preservative Fluid with cobas HPV Test

Ono Pharmaceutical discloses AXL inhibitors

Nichi-Iko Pharmaceutical to acquire Sagent Pharmaceuticals

Gilead Sciences describes HIV reverse transcriptase inhibitors

Merck & Co. develops orexin OX2 receptor antagonists

LG Life Sciences presents FFAR4 agonists

Multiple doses of intravenous echinocandin CD-101 safe and well tolerated in phase I study

Alios BioPharma announces agents for picornavirus infections

Regulatory submissions planned for niraparib following phase III results

Vernalis completes CCP-08 study

Topline results from pivotal European study of Infacort in pediatric adrenal insufficiency

Ono Pharmaceutical licenses rights to Celyad's NKR-2 in Japan, South Korea and Taiwan

GlyRS shows promise as a therapeutic target for cancer

FDA grants orphan drug designation to ZW-33

Karyopharm's selinexor granted U.S. orphan status for soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...